According to brokerage Jefferies, the average drug development cycle spans 8 to 10 years, with success rates below 10% and ...

Study suggests gasdermin D inhibition may protect mice by blocking release of cellular contents into the extracellular ...

Proteins represent 95% of drug targets designed to combat disease, according to Yvonne Tan, PhD, from Nuclera.

Microsoft Scientific Discovery is an AI-powered research-focused platform designed for scientists, research institutions, and ...

Colorado BioScience Association (CBSA) commends the Colorado Office of Economic Development and International Trade (OEDIT) for awarding $3.135 Million in Commercialization Infrastructure grants under ...

Radyus Research, a U.S.-based drug development organization, and Eurofins CDMO Alphora, a Canadian contract development and ...

Insilico Medicine ("Insilico"), in collaboration with research partner at Huadong Medicine Company, today announced the ...

Collaboration combines Nuclera’s eProtein Discovery System with Cytiva’s Biacore SPR system.

Waters Corporation  today announced the launch of the BioResolvetm Protein A Affinity Columns with MaxPeaktm Premier Technology, providing precise titer measurements. This launch marks the first set ...

Biopharma Industry Landscape Report—uncover key trends in obesity, oncology, immunology, and AI, plus top stock picks and ...

Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ ...